Revuforj is Syndax's second first-in-class approval for 2024, coming after the company and partner Incyte got a green light ...

AI-powered chatbots will enhance HCP engagement, while comprehensive customer lifetime value prediction will enable more ...

Last night, news broke that President-Elect Donald Trump had nominated Robert F Kennedy Jr (aka RFK Jr) as US Health ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

23andMe's big push into drug development, announced with great fanfare almost a decade ago, has ended with a whimper and ...

This 18th-20th February, 2025, London will host the premier HR event for European Life Sciences. Join CHROs, CPOs, and HR ...

The Life Sciences Industry Report: Trends & Predictions 2025 is built for those who are serious about growth, innovation, and ...

It came as AZ reported its third-quarter results, headlined by a 20% increase in revenues to $12.95 billion, which will be discussed in full at a meeting today, along with other pressing matters, such ...

Summit and Akeso's ivonescimab attracted headlines earlier this year when it was shown to be more effective than anti-PD-1 ...

"Slingshot represents an opportunity to bridge the gap between academic innovation and clinical development of a novel ...

A new report says that London is the top city in Europe for the life sciences industry, and ranks third worldwide after ...

Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) ...